

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

Patent Application of:  
Toshihiro Nakajima et al.

Confirmation No.: 6763

Application No.: 10/568,823

Art Unit: Not Yet Assigned

Filed: February 21, 2006

Examiner: Not Yet Assigned

---

For: THERAPEUTIC AGENT FOR  
AUTOIMMUNE DISEASE

New York, New York  
August 15, 2006

**SECOND PRELIMINARY AMENDMENT**

U.S. Patent and Trademark Office  
220 20th Street S.  
Customer Window, Mail Stop Amendment  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, VA 22202

Dear Sir:

**INTRODUCTORY COMMENTS**

Further to the first Preliminary Amendment filed February 21, 2006, please further amend the above-identified U.S. patent application, prior to examination on the merits, as follows:

**Amendments to the Specification** are reflected in the listing of claims which begins on page 3 of this paper.

**Amendments to the Drawings** begin on page 4 of this paper and include both an attached replacement sheet and an annotated sheet showing changes.

**Remarks/Arguments** begin on page 5 of this paper.

No additional fee is required.

In the event a fee is required or if any additional fee during the prosecution of this application is not paid, the Patent Office is authorized to charge any underpayment or credit any overpayment to Deposit Account No. 50-2215.

### **CONTINGENT EXTENSION REQUEST**

If this communication is filed after the shortened statutory time period had elapsed and no separate Petition is enclosed, the Commissioner of Patents and Trademarks is petitioned, under 37 CFR 1.136(a), to extend the time for filing a response to the outstanding Office Action by the number of months which will avoid abandonment under 37 CFR 1.135. The fee under 37 CFR 1.17 should be charged to our Deposit Account No. 50-2215.